Business Wire

AMCS Acquires Qv21 Technologies, Strengthening Its Transportation Management Capabilities

4.9.2024 15:00:00 CEST | Business Wire | Press release

Share

Qv21 Technologies’ fleet management and logistics SaaS solutions to support improved waste-to-resource conversion and sustainability for organizations

AMCS, a global leader of sustainability software for foundational industries, announced today its acquisition of Qv21 Technologies, a leading provider of fleet management and logistics SaaS solutions for short-haul, bulk commodity transportation, for an undisclosed amount.

Founded in 2009 in Austin, Texas, Qv21 Technologies enables short-haul and bulk commodity trucking companies of all sizes to increase operational visibility and improve overall efficiency. With their mission of enabling Logistics Without Barriers™, Qv21’s powerful solution, The LogisticsFramework™ (TLF), streamlines business processes from order to invoice. Backed with robust data management, workflow automation, and analytics capabilities, Qv21 ensures organizations are in complete control of their operations while boosting their savings and profit margins.

The innovative fleet management and logistics solutions by Qv21 Technologies, along with its North American footprint and focus on bulk material transportation, are highly complementary to the AMCS Platform, benefiting customers of both organizations. The acquisition empowers AMCS to expand the capabilities of the AMCS Platform, enabling resource-intensive industries to achieve their sustainability goals faster, more efficiently, and profitably.

“Qv21 Technologies has consistently offered innovative solutions built for short-haul, bulk commodity transportation companies, enhancing operational excellence for leading organizations, including those in the waste and recycling sectors,” said Jonathan Currie, CEO, Qv21 Technologies. “Qv21's commitment to 'Logistics Without Barriers' boosts efficiency and profitability for transporters. Beyond the opportunities for business expansion, our partnership with AMCS further strengthens this pursuit of operational excellence for our clients and accelerates our collective vision for greater sustainability.“

This acquisition paves the way for several synergistic opportunities to be realized, specifically aiding organizations in the long-haul transport of bulk commodities that can support a more circular economy vision. Materials that were previously considered waste and destined for landfill sites can now be effectively directed towards reuse or recycling facilities. With Qv21, AMCS can provide organizations with a solution for a more structured, efficient approach to resource utilization and improved waste management, translating to meaningful progress toward their sustainability goals.

“The strategic addition of Qv21 Technologies signifies a crucial advancement for AMCS, reinforcing our position at the forefront of Performance Sustainability,” explained, Jimmy Martin, co-founder and CEO, AMCS. “This partnership provides tremendous opportunities, specifically for companies engaged within bulk material transportation, to reach their sustainability goals faster. The features that Qv21 brings to the table serve to enhance our capabilities at AMCS, strengthening our ability to support our clients' drive towards enhanced resource management, greater efficiency, sustainability, growth, and profitability.”

AMCS’ Performance Sustainability Suite is the operating system for foundational industries that makes sustainability and profitability possible. The suite manages the running of day-to-day operations such as contracts and pricing, logistics and transportation, materials and resources, health and safety, and sustainability intelligence. The AMCS Performance Sustainability Suite drives growth and profitability, optimizes efficiency and safety, powers corporate sustainability initiatives, and prepares businesses for the circular economy and the future. With AMCS, businesses can improve performance and scale more easily, enabling foundational industry professionals to leave the planet in a better way than they found it.

About Qv21 Technologies
Founded in 2009, Qv21 Technologies is an industry-leading SaaS company specializing in Transportation Management Systems for short-haul, bulk commodity transport. Dedicated to building cloud-based tools, Qv21 supports transporters, carriers, and commodity buyers in navigating industry challenges.

Qv21 Technologies’ flagship solution, The LogisticsFramework™ (TLF), increases operational visibility and streamlines business processes, from order to invoice. As a committed technology provider to trucking companies of all sizes, Qv21 makes increasing savings and profit margins achievable, restoring control of operations back to the organization. Learn more at www.qv21.com

About AMCS
At AMCS we are focused on Performance Sustainability – enabling resource-intensive industries to boost sustainability and profitability. Built on decades of experience, our purpose-built software solutions are designed by people who understand your business, providing practical solutions for the resources, waste, recycling, transportation, manufacturing, and utilities industries.

Headquartered in Ireland, and with offices in Europe, the USA, and Australia, AMCS is a global market leader with over 1,300 mission-driven team members. The combined expertise of our team allows AMCS to deliver innovative solutions and extensive insight, helping customers to drive growth and achieve lasting success. As a trusted global partner, we work with 3800 customers in more than 80 countries delivering digital solutions that create meaningful and measurable impact by increasing customer satisfaction, enhancing sustainability, and boosting margins.

At AMCS, we're ready to innovate with you - deploying our experts, processes, and technology to drive your business forward and prepare you for success in a more sustainable, net zero carbon future. Learn more at: www.amcsgroup.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20240904279752/en/

Contacts

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye